Profile data is unavailable for this security.
About the company
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
- Revenue in USD (TTM)2.00m
- Net income in USD43.85m
- Incorporated2011
- Employees13.00
- LocationOramed Pharmaceuticals Inc1185 AVENUE OF THE AMERICAS, 3RD FLOORNEW YORK 10036United StatesUSA
- Phone+1 (646) 844-1164
- Fax+1 (845) 818-3588
- Websitehttps://oramed.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genelux Corp | 0.00 | -31.87m | 116.70m | 24.00 | -- | 5.28 | -- | -- | -0.8803 | -0.8803 | 0.00 | 0.4943 | 0.00 | -- | -- | 0.00 | -97.69 | -125.27 | -116.81 | -- | -- | -- | -- | -830.46 | -- | -- | 0.00 | -- | -95.29 | -- | -5.56 | -- | -26.46 | -- |
| Jyong Biotech Ltd | 0.00 | -2.95m | 117.84m | 29.00 | -- | -- | -- | -- | -0.0397 | -0.0397 | 0.00 | -0.3027 | 0.00 | -- | -- | 0.00 | -13.35 | -- | -127.41 | -- | -- | -- | -- | -- | -- | -1.96 | 2.79 | -- | -- | -- | 31.39 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -108.01m | 119.82m | 44.00 | -- | 2.64 | -- | -- | -2.01 | -2.01 | 0.00 | 0.8362 | 0.00 | -- | -- | 0.00 | -80.47 | -37.96 | -103.67 | -40.71 | -- | -- | -- | -46,390.86 | -- | -- | 0.2099 | -- | -- | -- | 16.14 | -- | 4.84 | -- |
| Black Diamond Therapeutics Inc | 70.00m | 21.50m | 126.48m | 24.00 | 6.12 | 1.00 | 5.79 | 1.81 | 0.3629 | 0.3629 | 1.23 | 2.22 | 0.4736 | -- | -- | 2,916,667.00 | 14.54 | -42.24 | 16.58 | -46.05 | -- | -- | 30.71 | -- | -- | -- | 0.00 | -- | -- | -- | 15.48 | -- | -- | -- |
| AVITA Medical Inc | 72.40m | -48.56m | 127.43m | 260.00 | -- | -- | -- | 1.76 | -1.81 | -1.81 | 2.70 | -0.2186 | 1.00 | 1.63 | 7.50 | 278,461.50 | -67.07 | -- | -147.57 | -- | 84.81 | -- | -67.06 | -- | 0.5519 | -8.20 | 1.19 | -- | 28.14 | -- | -74.80 | -- | -- | -- |
| Oramed Pharmaceuticals, Inc. | 2.00m | 43.85m | 129.36m | 13.00 | 3.23 | 0.6529 | 2.94 | 64.68 | 1.01 | 1.01 | 0.0478 | 4.98 | 0.0104 | -- | -- | 153,846.20 | 22.72 | -- | 23.30 | -- | 0.65 | -- | 2,190.40 | -- | -- | -- | 0.00 | -- | -100.00 | -- | -444.98 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -67.51m | 132.70m | 28.00 | -- | 1.03 | -- | -- | -5.51 | -5.51 | 0.00 | 7.35 | 0.00 | -- | -- | 0.00 | -49.34 | -69.78 | -55.11 | -97.84 | -- | -- | -- | -5,894.85 | -- | -- | 0.00 | -- | -- | -- | 9.85 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -33.47m | 133.25m | 22.00 | -- | 3.45 | -- | -- | -2.85 | -2.85 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -74.93 | -188.44 | -101.88 | -723.53 | -- | -- | -- | -6,003.20 | -- | -- | 0.00 | -- | -100.00 | -- | -20.42 | -- | -- | -- |
| vTv Therapeutics Inc | 17.00k | -23.47m | 133.39m | 23.00 | -- | 1.89 | -- | 7,846.40 | -3.32 | -3.32 | 0.0024 | 17.91 | 0.0002 | -- | -- | 739.13 | -39.79 | -96.30 | -46.08 | -- | -- | -- | -166,935.30 | -775.06 | -- | -- | 0.0046 | -- | -- | -18.12 | 8.83 | -- | -- | -- |
| Spero Therapeutics Inc | 40.55m | -43.84m | 134.65m | 32.00 | -- | 5.08 | -- | 3.32 | -0.7949 | -0.7949 | 0.7299 | 0.4705 | 0.4283 | -- | 1.45 | 1,267,156.00 | -46.31 | -35.16 | -69.26 | -42.63 | -- | -- | -108.11 | -111.75 | -- | -- | 0.00 | -- | -53.77 | 21.46 | -400.65 | -- | -- | -- |
| Vaxart Inc | 148.20m | -50.70m | 135.88m | 105.00 | -- | 4.84 | -- | 0.9168 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| Sangamo Therapeutics Inc | 32.88m | -108.91m | 138.20m | 183.00 | -- | 19.96 | -- | 4.20 | -0.4428 | -0.4428 | 0.1326 | 0.0194 | 0.3289 | -- | 5.97 | 179,644.80 | -108.96 | -30.73 | -204.29 | -37.33 | -- | -- | -331.28 | -147.59 | -- | -- | 0.00 | -- | -67.20 | -10.81 | 62.01 | -- | -58.10 | -- |
| HST Global Inc | 0.00 | -212.63k | 139.70m | 1.00 | -- | 8.48 | -- | -- | -0.0107 | -0.0107 | 0.00 | 0.1167 | 0.00 | -- | -- | -- | -6.87 | -27.80 | -8.09 | -60.19 | -- | -- | -- | -- | -- | -107.48 | 0.0433 | -- | -- | -- | -45.42 | -- | -- | -- |
| Nkarta Inc | 0.00 | -102.61m | 139.93m | 105.00 | -- | 0.4141 | -- | -- | -1.39 | -1.39 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -21.39 | -29.78 | -22.36 | -31.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.41 | -- | 17.99 | -- |
| Prelude Therapeutics Inc | 10.50m | -111.77m | 140.19m | 131.00 | -- | 2.16 | -- | 13.35 | -1.47 | -1.47 | 0.1382 | 1.03 | 0.0719 | -- | -- | 80,152.67 | -76.56 | -47.36 | -88.86 | -51.44 | -- | -- | -1,064.50 | -7,615.23 | -- | -- | 0.00 | -- | -- | -- | -4.38 | -- | -0.4137 | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 141.07m | 97.00 | -- | 1.30 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
Data as of Feb 13 2026. Currency figures normalised to Oramed Pharmaceuticals Inc's reporting currency: US Dollar USD
22.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 31 Dec 2025 | 3.17m | 7.96% |
| Aquamarine Financial (Cayman) Ltd.as of 31 Dec 2025 | 1.97m | 4.96% |
| Murchinson Ltd.as of 30 Sep 2025 | 1.75m | 4.40% |
| Boothbay Fund Management LLCas of 30 Sep 2025 | 845.39k | 2.12% |
| Marshall Wace LLPas of 31 Dec 2025 | 259.06k | 0.65% |
| Rathbones Investment Management Ltd.as of 31 Dec 2025 | 233.02k | 0.59% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 147.50k | 0.37% |
| Wells Fargo Clearing Services LLCas of 31 Dec 2025 | 130.59k | 0.33% |
| Merrill Lynch International (Investment Management)as of 30 Sep 2025 | 128.03k | 0.32% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 118.85k | 0.30% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
